ID
16710
Descripción
Sponsor: OSI Pharmaceuticals Information provided by (Responsible Party): Astellas Pharma Inc (OSI Pharmaceuticals) A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent Tarceva® (erlotinib) following complete tumor resection with or without adjuvant chemotherapy in patients with stage IB-IIIA non-small cell lung carcinoma who have EGFR-positive tumors. See https://clinicaltrials.gov/ct2/show/NCT00373425 Part of study: Prevention and Treatment of Skin, Hair and Nail Reactions Due to Study Drug Administration
Link
https://clinicaltrials.gov/ct2/show/NCT00373425
Palabras clave
Versiones (2)
- 1/8/16 1/8/16 -
- 27/9/16 27/9/16 -
Subido en
1 de agosto de 2016
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY-NC 3.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
Prevention and Treatment of Skin, Hair and Nail Reactions, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425
Prevention and Treatment of Skin, Hair and Nail Reactions Due to Study Drug Administration, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425
Descripción
Prevention and Treatment of Skin, Hair and Nail Reactions Due to Study Drug Administration
Descripción
Record all topical creams, gels, oral or IV medications, and/or other interventions used to prevent and treat skin, hair and nail reactions (includes rash, skin fissures, nail and hair changes, etc) due to study drug administration. Moisturizers and sunscreens used to prevent and treat skin reactions should be recorded on the Moisturizers and Sunscreens CRF page.
Tipo de datos
text
Alias
- UMLS CUI [1,1]
- C0087111
- UMLS CUI [1,2]
- C0221743
- UMLS CUI [2,1]
- C0087111
- UMLS CUI [2,2]
- C0018500
- UMLS CUI [3,1]
- C0087111
- UMLS CUI [3,2]
- C0234909
Descripción
Indication Prophylaxis
Tipo de datos
boolean
Alias
- UMLS CUI [1,1]
- C3146298
- UMLS CUI [1,2]
- C0199176
Descripción
Drug Administration Route
Tipo de datos
integer
Alias
- UMLS CUI [1]
- C0013153
Descripción
Drug Administration Route
Tipo de datos
text
Alias
- UMLS CUI [1]
- C0013153
Descripción
Specific Indication should be reported on the Adverse Event (Including Baseline Signs/Symptoms) CRF page, unless the intervention was given as a prophylaxis.
Tipo de datos
integer
Alias
- UMLS CUI [1]
- C3146298
Descripción
Indication
Tipo de datos
text
Alias
- UMLS CUI [1]
- C3146298
Descripción
Date Started
Tipo de datos
date
Alias
- UMLS CUI [1]
- C3173309
Descripción
Date Stopped
Tipo de datos
date
Alias
- UMLS CUI [1]
- C1531784
Descripción
Date Stopped
Tipo de datos
boolean
Alias
- UMLS CUI [1]
- C1531784
Similar models
Prevention and Treatment of Skin, Hair and Nail Reactions Due to Study Drug Administration, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425
C0221743 (UMLS CUI [1,2])
C0087111 (UMLS CUI [2,1])
C0018500 (UMLS CUI [2,2])
C0087111 (UMLS CUI [3,1])
C0234909 (UMLS CUI [3,2])
C0221743 (UMLS CUI [1,2])
C0087111 (UMLS CUI [2,1])
C0018500 (UMLS CUI [2,2])
C0087111 (UMLS CUI [3,1])
C0234909 (UMLS CUI [3,2])
C0199176 (UMLS CUI [1,2])